Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLV213 Phase 1 MAD Study in Healthy Volunteers
NCT06146374Phase 1Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2024
- Primary completion
- Jul 2024
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SLV213 in coronavirus disease 2019 (COVID-19) (3 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Frequency of Treatment-Emergent Adverse Events by Maximum Severity, Frequency of Serious Adverse Events and 2 more. Started Apr 2024; status: terminated.
02
Drugs
SLV213
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06146374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06146374.